Cat.No. : AAV00093Z
Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml
Serotype: AAV Serotype 6 Storage: -80 ℃
| Cat. No. | AAV00093Z |
| Description | Synapsin-GFP AAV (Serotype 6) is the serotype 6 AAV which express eGFP under the Synapsin promoter which restricts transgene expression only in neurons. |
| Reporter | GFP |
| Serotype | AAV Serotype 6 |
| Target Gene | Synapsin-GFP |
| Product Type | Adeno-associated virus |
| Application | 1. Determination of optimal MOI (multiplicity of infection), administration methods etc. 2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue. 3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery. |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. | |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
Nonsurgical gene delivery to the brain can be achieved by intravenous injection of viral vectors coupled with transcranial MRI-guided focused ultrasound (MRIgFUS) to temporarily and locally permeabilize the blood-brain barrier. The choice of vector and promoter can provide neuronal expression in the brain while limiting biodistribution and expression in peripheral organs. Here, researchers evaluated the amount of viral DNA from serotypes AAV9, AAV6, and chimeric AAV1&2 expressing green fluorescent protein (GFP) under the neuron-specific synapsin promoter (syn). AAV was injected intravenously during MRIgFUS targeting of the striatum and hippocampus of mice. The syn promoter resulted in undetectable levels of GFP expression in peripheral organs. In the liver, biodistribution was 12.9-fold and 4.4-fold higher for AAV9 and AAV1&2, respectively, compared with AAV6. AAV6-syn-GFP and AAV1&2-syn-GFP showed comparable percentages of GFP-positive neurons in FUS-targeted regions of the brain. In conclusion, MRIgFUS-mediated AAV6-syn-GFP gene delivery had lower off-target biodistribution in the liver compared to AAV9 and AAV1&2, while providing neuronal GFP expression in the striatum and hippocampus.
MRIgFUS delivered AAV1&2-syn-GFP and AAV6-syn-GFP (3 × 109 VG/g) from the blood to the hippocampus, striatum, thalamus, and cortex, resulting in GFP transgene expression (Figure 1). Animals injected with both AAV1&2-syn-GFP and AAV6-syn-GFP showed clear GFP expression in the hippocampus (Figure 1a, b). At higher magnification, GFP expression was seen throughout the cell bodies and processes in the hippocampus (Figure 1c, h), striatum (Figure 1d, i), cortex (Figure 1e, j), and thalamus (Figure 1f, k). GFP-positive cell bodies were completely colocalized with NeuN-positive (neuronal marker) cells (Figure 1g, l). This confirmed the presence of neuron-specific transgene expression in the brain under the syn promoter in combination with AAV1&2 and 6 serotypes.
Figure 1. Transgene expression in neurons after MRIgFUS delivery of AAV to the hippocampus, striatum, thalamus, and cortex. (Weber-Adrian D, et al., 2021)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Synapsin-GFP AAV (Serotype 6)'s versatility in applications, from in vitro culture to in vivo studies, makes it a vital tool in our laboratory’s research arsenal."
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
